- CEO
- Guillaume Daniellot
- Full Time Employees
- 11,824
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Peter Merian-Weg 12 Basel BS Switzerland 4002
- IPO Date
- Dec 19, 2014
- Business
- Straumann Holding AG stands as a prominent global entity in the realm of advanced oral care solutions. The company is actively engaged in the research, development, manufacturing, and global distribution of comprehensive offerings spanning tooth replacement, restoration, and orthodontic treatments. Its extensive portfolio encompasses a broad spectrum of products, including sophisticated dental implant systems designed for both tissue and bone integration, made from materials such as titanium, titanium alloy, and ceramics. Beyond implants, Straumann provides a wide array of specialized instruments, innovative CAD/CAM prosthetics for precision restorations, and advanced biomaterials crucial for tissue regeneration and oral healing. In the field of orthodontics, its clear aligner systems, notably ClearCorrect, offer discreet tooth correction alternatives. A significant focus is placed on digital dentistry, with solutions like intraoral scanners, 3D printers, milling machines, and integrated software platforms such as Straumann AXS, which streamline workflows from diagnosis to treatment. These digital innovations are critical for enhancing precision and efficiency across various therapeutic areas. Serving a diverse global clientele, Straumann's products and services reach general dentists, dental specialists like oral surgeons and orthodontists, dental laboratories, and large dental service organizations (DSOs) across more than 100 countries through a robust network of subsidiaries and partners. The company further reinforces the dental profession through comprehensive training and education programs, often in collaboration with leading academic institutions. Recent strategic developments highlight the company's dynamic approach. For the full year 2024, Straumann reported substantial revenue of CHF 2.5 billion, reflecting a strong organic growth of 13.7%. The company also saw its net profit rise to CHF 338.3 million in 2024. In a strategic realignment in Q2 2024, Straumann divested its direct-to-consumer clear aligner business, DrSmile, to Impress Group, while retaining a 20% minority stake, to concentrate on its core go-to-market strategies. Innovation continued in 2024 with the launch of the iEXCEL premium implant system in North America and the AlliedStar intraoral scanner in China. Looking to 2025, the company launched the SIRIOS X3 intraoral scanner, integrating seamlessly into its digital ecosystem, and continues to expand its AXS platform globally. A notable expansion in November 2025 included the establishment of its first integrated manufacturing, education, and innovation campus in China. Headquartered in Basel, Switzerland, Straumann Holding AG, founded in 1954, continues to drive advancements aimed at enhancing oral health and restoring patient confidence worldwide.